1. Tumor endothelial cells as a potential target of metronomic chemotherapy
   Ji Yoon Kim et al, 2019, Archives of Pharmacal Research CrossRef
2. Multicenter Phase II Study of a New Effective S-1 and Irinotecan Combination Schedule in Patients with Unresectable Metastatic or Recurrent Colorectal Cancer
   null null et al, 2013, Clinical Medicine Insights: Oncology CrossRef
3. Prognostic Value of CD109+ Circulating Endothelial Cells in Recurrent Glioblastomas Treated with Bevacizumab and Irinotecan
   Lucia Cuppini et al, 2013, PLoS ONE CrossRef
4. Targeted microbubbles carrying lipid-oil-nanodroplets for ultrasound-triggered delivery of the hydrophobic drug, combretastatin A4
   Antonia Charalambous et al, 2021, Nanomedicine: Nanotechnology, Biology and Medicine CrossRef
5. The differential effects of metronomic gemcitabine and antiangiogenic treatment in patient-derived xenografts of pancreatic cancer: treatment effects on metabolism, vascular function, cell proliferation, and tumor growth
   Donald T. Yapp et al, 2016, Angiogenesis CrossRef
6. Long term outcomes of phase I/II study of palliative triple metronomic chemotherapy in platinum-refractory/early failure oral cancer
   Sachin Babanrao Dhumal et al, 2023, The Lancet Regional Health - Southeast Asia CrossRef
7. Rationale for the use of metronomic chemotherapy in gastrointestinal cancer
   Roberto Filippi et al, 2018, Expert Opinion on Pharmacotherapy CrossRef
8. Metronomic chemotherapy in metastatic colorectal cancer
   In Sook Woo et al, 2017, Cancer Letters CrossRef
9. Clinical overview of metronomic chemotherapy in breast cancer
   Elisabetta Munzone et al, 2015, Nature Reviews Clinical Oncology CrossRef
10. Crystallization of the Multi-Receptor Tyrosine Kinase Inhibitor Sorafenib for Controlled Long-Term Drug Delivery Following a Single Injection
    Victoria Lai et al, 2021, Cellular and Molecular Bioengineering CrossRef